ISPOR Publishes New Top 10 HEOR Trends Report

Published Jan 16, 2024

New Health Economics and Outcomes Research Trends Report Focuses on Horizon Scanning for Key Themes Impacting Healthcare in 2024-2025

Lawrenceville, NJ, USA—January 16, 2024—ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) announced today the publication of its “2024-2025 Top 10 HEOR Trends Report.” The Society publishes this report as part of its horizon scanning and monitoring of the trends that affect healthcare decision making around the world. This marks the fifth publication of the ISPOR Top 10 HEOR Trends Report that is a biennial publication. The report is based on input from its members and strategic curation from its Health Science Policy Council.

Real-world evidence appears again as the #1 trend in this report. The use of real-world evidence in healthcare decision making is becoming ever more tangible and is increasingly used to augment randomized controlled trials as well as to provide additional insights into safety and effectiveness. Drug pricing is also a recurring theme, appearing as #2 in this report. Drug pricing has appeared in some form in each of the past trends reports. Artificial intelligence (AI) returns to the trends list as the #3 trend in this report. AI has entered the public conversation in a pronounced way as many people are becoming comfortable with platforms, such as ChatGPT, as a tool in their daily lives. A new topic for this report and appearing as the #4 trend—fostering innovation—focuses on the balance of incentivizing the development of innovative, new technologies with affordable pricing. Health equity returns as the #5 trend, having first appeared in the previous report. 

The full list of the top 10 trends outlined in the 2024-2025 report include:

  1. Real-World Evidence
  2. Drug Pricing
  3. Artificial Intelligence
  4. Fostering Innovation
  5. Health Equity
  6. Accelerated Drug Approvals
  7. Value Measurement
  8. Patient Centricity
  9. Precision Medicine
  10. Public Health

CEO and Executive Director Rob Abbott stated, “The Top 10 HEOR Trends Report is an important horizon scanning publication for ISPOR. The trends are identified through a thorough review of where healthcare is heading, a member survey, and curation by the Society’s Health Science Policy Council and the ISPOR Science Office. This report is an important vehicle for ISPOR to communicate the essential role that HEOR plays to improve healthcare.”

Additional information on the “ISPOR 2024-2025 Top 10 HEOR Trends,” including a full download of the report, can be found here.

###

 

ABOUT ISPOR
ISPOR—The Professional Society for Health Economics and Outcomes Research
(HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Website
 | LinkedIn  | Twitter (@ispororg)  |  YouTube  |  Facebook  |  Instagram  

Related Stories

ISPOR Releases Emerging Good Practices Guidance on Quantifying Specialized Knowledge in Healthcare

Nov 6, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that identifies existing structured expert elicitation protocols that can support healthcare decision making and provides important insights on how to choose which protocols may be the most appropriate for different scenarios, such as time-constrained decisions, early-stage technology assessments, and public health policies.

ISPOR Announces 2024 Health Economics and Outcomes Research Award Honorees

Oct 14, 2024

ISPOR—The Professional Society for Health Economics and Outcomes Research announced today the recipients of its 2024 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards.

Cracking the Code on Medicare's Drug Price Negotiations

Oct 1, 2024

ISPOR announced the publication of a study that provides estimates of how the Centers for Medicare & Medicaid Services (CMS) may have determined initial price offers for the first 10 drugs selected for Medicare price negotiation. A prepublication version of the study was released online on the same day the CMS announced it reached agreements for lower drug prices.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×